A detailed history of Nuveen Asset Management, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 83,787 shares of NUVL stock, worth $7.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,787
Previous 106,070 21.01%
Holding current value
$7.38 Million
Previous $8.05 Million 6.52%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $1.5 Million - $2.5 Million
-22,283 Reduced 21.01%
83,787 $8.57 Million
Q2 2024

Aug 09, 2024

BUY
$62.76 - $81.61 $2.63 Million - $3.42 Million
41,862 Added 65.2%
106,070 $8.05 Million
Q1 2024

May 13, 2024

BUY
$72.35 - $88.99 $9,188 - $11,301
127 Added 0.2%
64,208 $4.82 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $146,688 - $277,608
3,458 Added 5.7%
64,081 $4.72 Million
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $15,608 - $19,890
-399 Reduced 0.65%
60,623 $2.79 Million
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $103,799 - $196,681
4,402 Added 7.77%
61,022 $2.57 Million
Q1 2023

May 15, 2023

SELL
$25.42 - $33.52 $97,282 - $128,281
-3,827 Reduced 6.33%
56,620 $1.48 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $424,487 - $836,328
22,995 Added 61.4%
60,447 $1.8 Million
Q3 2022

Nov 14, 2022

SELL
$13.55 - $19.92 $54,728 - $80,456
-4,039 Reduced 9.73%
37,452 $728,000
Q2 2022

Aug 15, 2022

BUY
$7.4 - $15.07 $110,741 - $225,522
14,965 Added 56.42%
41,491 $563,000
Q1 2022

May 16, 2022

BUY
$11.65 - $19.57 $125,552 - $210,905
10,777 Added 68.43%
26,526 $319,000
Q3 2021

Nov 12, 2021

BUY
$18.25 - $38.35 $287,419 - $603,974
15,749 New
15,749 $355,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.79B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.